menu
    • menu
    [{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GRF6021","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Alkahest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CXCR3 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CXCR3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkahest \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Alkahest

    Menu

    Alkahest

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GRF6021

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkahest to Present Positive Data from Phase 2 Clinical Trial at the 15th International Conference on Alzheime...

                            Details : In the phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints and was safe and well tolerated by study participants.

                            Product Name : GRF6021

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : GRF6021

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Grifols International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKST4290

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290

                            Details : The company has dosed the first subject in AKST4290-205, which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatment-naïve neovascular AMD patients.

                            Product Name : AKST4290

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2020

                            Lead Product(s) : AKST4290

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Grifols International

                            Deal Size : $146.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for...

                            Details : Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular and ophthalmic indications .

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            July 09, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Grifols International

                            Deal Size : $146.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Alkahest

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AKST4290

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in PD

                            Details : The trial, AKST4290-211, is funded in part by The Michael J. Fox Foundation for Parkinson’s Research and will evaluate the effect of AKST4290 on motor function in Parkinson’s disease.

                            Product Name : AKST4290

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 02, 2020

                            Lead Product(s) : AKST4290

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth